Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 17 Ovarian Neoplasms 11 Neoplasms 8 Fallopian Tube Neoplasms 8 Triple Negative Breast Neoplasms 7 Prostatic Neoplasms 6 Neoplasm Metastasis 6 Pancreatic Neoplasms 4 Endometrial Neoplasms 4 Neuroendocrine Tumors 3 Glioma 3 Glioblastoma 3 Carcinoma, Ovarian Epithelial 3 Recurrence 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Fanconi Anemia, Complementation Group D1 2 Cholangiocarcinoma 2 Uveal Melanoma 1 Urogenital Neoplasms 1 Solid Tumors 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma, Synovial 1 SCLC,Extensive Stage 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Platinum-sensitive Ovarian Cancer 1

Interventions

Cyclophosphamide 22 fludarabine 20 venetoclax 8 Whole-Body Irradiation 8 Mycophenolic Acid 8 Standard of Care 6 Mesna 6 Melphalan 6 Azacitidine 6 fludarabine phosphate 5 Sirolimus 5 thymoglobulin 4 Thiotepa 4 Tacrolimus 4 Specimen Handling 4 Filgrastim 4 Cytarabine 4 entrectinib 3 daratumumab 3 cobimetinib 3 alectinib 3 Vemurafenib 3 Surveys and Questionnaires 3 Rituximab 3 Practice Guidelines as Topic 3 Palliative Care 3 Granulocyte Colony-Stimulating Factor 3 Busulfan 3 Bortezomib 3 Blood Specimen Collection 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Hematologic Neoplasms × olaparib × Clear all

NCT03486873 2026-06-05

MK-3475-587

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡